Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Παρόμοια τεκμήρια

• Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
  ανά: Jabbour, Elias, κ.ά.
  Έκδοση: (2008)
• Very Long-term Follow-Up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy
  ανά: Kantarjian, Hagop, κ.ά.
  Έκδοση: (2012)
• Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
  ανά: Quintás-Cardama, Alfonso, κ.ά.
  Έκδοση: (2009)
• Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
  ανά: Jabbour, Elias, κ.ά.
  Έκδοση: (2011)
• Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
  ανά: Ravandi, Farhad, κ.ά.
  Έκδοση: (2010)